CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver Developing Topics (late-breaking) virtual ...

Long-term efficacy and safety data on PALSONIFYTM (paltusotine) in acromegaly to be presented, including evidence of both ...

RAJSHAHI, July 10, 2025 (BSS) - A poster presentation competition on 'Efficiency Pioneers: Time Study Challenge' was held at Rajshahi University of Engineering and Technology (RUET) on Wednesday.

Data from the Phase 1 clinical trial of novel KCNK13 inhibitor showed good CNS exposure and was generally ...

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin ...

Poster #3 : Advancing buntanetap: comparative pharmacokinetic characterization of the original semi-crystalline with the novel crystalline form in animals and humans.

--Annovis Bio, Inc., a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease, today ...

In addition, Crinetics will present three poster presentations: one evaluating symptom stability in acromegaly, one analyzing patient-reported outcomes from both PATHFNDR-1 and PATHFNDR-2 and another ...

SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...

Key Findings from the Poster Presentations: Results from participants receiving oral, once-daily mavorixafor monotherapy showed that mavorixafor durably increased mean ANC from baseline over the 6 ...

Aquestive Therapeutics, Inc. announced that it will present results from studies on its investigational product, Anaphylm™ (epinephrine) Sublingual Film, at the CFAAR Food Allergy Summit in ...